amr INDUSTRY ALLIANCE
UNITED AGAINST ANTIMICROBIAL RESISTANCE

AMR Industry Alliance

Overview

Representing the Major Sub-Sectors of the Life Sciences Industry

Who We Are

The largest life- sciences coalition set up to provide sustainable solutions to curb AMR

Our Vision


To contribute sustainable solutions by creating broad industry momentum and facilitating collaboration between the public and private sectors

A Shared Critical Global Challenge

Taking a leadership role to advance:

- WHO Global Action Plan on AMR
- Sustainable Development Goals
- UN Political Declaration on AMR

Representing the Major Sub-Sectors of the Life Sciences Industry



Our Structure



Provides strategic direction & oversight


Executes strategic plan & implements strategic initiatives

Drives forward AMR Industry Alliance mission & vision

Executes operations & governance and ensure ongoing communications

AMRIA Engagement

Partners







BUSINESS COUNCIL FOR THE UNITED NATIONS

Events









EXPERT MEETINGS ON ACCESS & secure




Publications








Publications







Events









Partners



United Nations



CDC

UNITED NATIONS FOUNDATION

AMRIA: Progress From Inception to Today

DEFENDER

2016–2018

- Davos Declaration on AMR
- Alliance founded at the G20, Berlin
- First progress report

EXPERT

2020–2022

- Second and third progress reports
- Manufacturing Standard launched

ADVOCATE

2023–2024

- Certification launched
- Call-to-Action
- UN High-Level Meeting on AMR
- Global Ministerial, Jeddah

2025

- Strategic Plan 2025–2030
- Wilton Park dialogue
- Africa CDC meeting
- WAAW webinar

2026

- MSPP Plenary, Rome
- World AMR Awareness Week
- Ministerial, Abuja (Dec 6–8)
- A&AU Brief 1

ROAD TO 2029

2027–2028

- A&AU and Manufacturing workshops
- UK G20 Presidency
- Penicillin centenary
- Ministerial, Brazil (proposed)

2029

- UN High-Level Meeting on AMR, UNGA

AMR Industry Alliance Key Priorities

Access and Appropriate Use Worldwide

- Lead industry engagement on initiatives with potential to pilot or scale new access models in LMICs
- Support responsible use alongside access to avoid misuse and the spread of resistance
- Ongoing engagement with WHO, GARDP, Africa CDC, and other access-focused partners

Global Advocacy to elevate the Business Voice on AMR

- Advance coordinated industry positions through the Multi-Stakeholder Platform on AMR
- Engage in key global moments, including the High-Level Ministerial Meeting, WHA, and UNGA
- Direct outreach to governments and other stakeholders to shape policy discussions

Responsible Manufacturing & Adherence to Standards

- Advance implementation of the Alliance manufacturing standard via independent BSI certification
- Promote responsible manufacturing as a core expectation across the antibiotic value chain
- Advocate for inclusion of manufacturing standards within public and donor procurement models

Our Structure: Working Groups

Executes strategic plan & implements strategic initiatives

Access-Appropriate Use

Drive progress towards sustainable and appropriate access to antimicrobials and diagnostics; working groups to meet jointly

Manufacturing

Accelerate the adoption of a manufacturing and environmental standards & certification across the supply chain

Ad hoc Task Force on Advocacy

Convened as needed to drive key advocacy and research & science initiatives

Membership & Finance

Ensure effective and efficient internal Alliance functions and membership recruitment

Key Activities for AMR Access & Appropriate Use

- **Driving follow-up from the High-Level Meeting on AMR** by translating commitments into concrete action
- Strengthening partnerships in LMICs through targeted stakeholder mapping and engagement**, aligned with the High-Level Ministerial Meeting in Nigeria**
- **Collaborating with governments, multilaterals, and implementers** before, during, and after the HLM
- **Building a shared evidence base** on access and appropriate use across income levels, identifying priority challenges, policy solutions, and gaps

Stewardship Prize

Awarded to 6 entities in LMICs (2021-2026)

The Stewardship Prize initiative recognizes established, innovative approaches to AMR stewardship in low- and middle-income countries (LMICs).



Principles for Pooled Procurement

The AMR Industry Alliance Principles for Pooled Procurement of AMR Products aims to support purchasers LMICs in establishing pooled procurement mechanisms (PPMs) for antimicrobial resistance products, including antibiotics and diagnostics.



Manufacturing and Certification Highlights

The only independent and certifiable standard for responsible antibiotic manufacturing

2022
- Standard published, facilitated by BSI
- Minimizes environmental risks contributing to AMR
- Certification pilots, Dec 2022 – Feb 2023

2023
- BSI launches its Minimized Risk of AMR certification (June)
- Third-party verification of compliance
- First certifications issued (November)

2024
- Certification with stakeholders: procurement, healthcare, investment
- Certification built into HLM advocacy
- Member adoption at own and supplier sites

2025
- Revised Standard published (May)
- Reflects implementation experience, WHO emissions guidance and the latest PNEC science

2026
- Revised Standard incorporated into BSI certification
- >200 products certified as of October
- Manufacturing Working Group marks 10 years (October)

BSI Certification **Update**

PRODUCTS CERTIFIED TO THE STANDARD

Up from 135 in May 2026, across Alliance members' supply chains. BSI expects to announce 200 certificates during World AMR Awareness Week.



SOURCE: BSI, AS OF OCTOBER 2026

EDAR 8, BRISBANE AUSTRALIA - AUGUST

EDAR 8 (August): Alliance-sponsored risk assessment workshop, feeding EMA's environmental risk guidance

Sponsor for environmental science AMR conference; risk assessment workshop with Pfizer, Roche and the University of Exter






OCTOBER

10-year anniversary of the Manufacturing Working Group, marked in October

The Faltering Antibiotic Pipeline

The AMR Industry Alliance is highlighting the **growing shortage of new antibiotics** through The Faltering Antibiotic Pipeline, building on the Leaving the Lab report to show how scientific barriers and a broken market are undermining antimicrobial innovation.





KEY EXAMPLES

01 Antimicrobial resistance threatens modern medicine and routine medical procedures

02 Antibiotics are ~100× less likely to succeed than other medicines in development

03 Only 7 new antibiotics approved in the past 5 years, compared with 4–6 per year in the 1980s

04 Urgent need for policy and market reforms to stabilize antibiotic R&D

Global Platforms and Events

WORLD AMR ANTIMICROBIAL RESISTANCE CONGRESS

AfricaCDC Centres for Disease Control and Prevention

CIDRAP









World AMR Awareness Week

HANDLE ANTIMICROBIALS WITH CARE

Antibiotics
Antivirals
Antifungals
Antiparasitics

CPHI

SETAC



33rd ECCMID EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES

Additional Network and Partnerships

USAID
FROM THE AMERICAN PEOPLE

CGD
CENTER FOR GLOBAL DEVELOPMENT

Nasdaq

GARDP
Global Antibiotic Research & Development Partnership


AMR Multi-Stakeholder Partnership Platform

Permanent Mission of Barbados to the UN

PERMANENT MISSION OF MALTA TO THE UN NEW YORK

TOILET BOARD COALITION

AMRIA in the News: Coverage across Mainstream & Trade Media

















amr INDUSTRY ALLIANCE
UNITED AGAINST ANTIMICROBIAL RESISTANCE

Learn more at: amrindustryalliance.org